Phase
Condition
Rheumatoid Arthritis
Joint Injuries
Arthritis And Arthritic Pain
Treatment
CT-P47
EU-approved RoActemra
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patient is male or female aged 18 to 75 years old, both inclusive.
Patient has had a diagnosis of RA according to the 2010 ACR/EULAR classificationcriteria for at least 24 weeks prior to the first administration of the study drug.
Exclusion
Exclusion Criteria:
Patient who has previously received investigational or licensed product; targetedsynthetic DMARD(s) (e.g., tofacitinib, baricitinib) for the treatment of RA and/oran interleukin-6 (IL-6) inhibitor for any purposes.
Patient who has previously received more than 1 biologic agents approved for thetreatment of RA.
Patient who has allergies to any of the excipients of study drug or any other murineand human proteins, or patient with a hypersensitivity to immunoglobulin products.
Study Design
Study Description
Connect with a study center
INTER CLINIC Piotr Adrian Klimiuk
Bialystok,
PolandSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.